Intra Cellular Therapies | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
Acadia Pharmaceuticals USD 755.99M 190.66M 2024-12
ALKERMES USD 291.15M 636.63M 2024-12
Biogen USD 2.38B 675.8M 2024-12
Bristol-Myers Squibb USD 10.35B 2.46B 2024-12
Cytokinetics USD 94.86M 47.97M 2024-12
Gilead Sciences USD 9.99B 4.95B 2024-12
Halozyme Therapeutics USD 115.85M 38.47M 2024-12
Intra Cellular Therapies USD 306.95M 157.36M 2024-12
J&J USD 6.12B 1.28B 2024-12
Neurocrine Biosciences USD 233M 116.1M 2024-12
Novartis USD 11.46B 2.15B 2024-12
Prothena USD 471.39M 47.87M 2024-12
RedHill Biopharma USD 7.28M 3K 2024-06
Supernus Pharmaceuticals USD 69.33M 37.66M 2024-12
United Therapeutics USD 1.7B 143.3M 2024-12



Intra Cellular Therapies Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Mar 2025.